lemma health

Halobetasol is highly effective at treating eczema, with success rates between 88-94% across multiple studies. Most patients see significant improvement or complete healing of their eczema.

Summary:

Halobetasol propionate cream was as effective as two other steroid creams (clobetasol and betamethasone) in treating severe atopic dermatitis. About 88-93% of patients showed significant improvement, with effects starting within 3 days for about 40% of patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 264

Severity: severe

Age: Not specified

Results:

All three treatments showed similar high success rates

---

Summary:

Halobetasol propionate ointment was more effective than diflucortolone valerate ointment in treating severe atopic dermatitis, with 91.5% of patients showing significant improvement compared to 83.6%. It also worked faster, with 70% of patients seeing improvements within 3 days, and had fewer side effects.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 120

Results:

Halobetasol propionate showed better overall success rate

---

---

The medication works quickly, with many patients seeing improvements within the first 3 days of treatment. This fast action makes it particularly useful for quick relief of symptoms.

Summary:

Halobetasol propionate ointment was more effective than diflucortolone valerate ointment in treating severe atopic dermatitis, with 91.5% of patients showing significant improvement compared to 83.6%. It also worked faster, with 70% of patients seeing improvements within 3 days, and had fewer side effects.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 120

Results:

Halobetasol propionate showed better overall success rate

---

Summary:

Halobetasol propionate 0.05% ointment was significantly more effective than vehicle (placebo) in treating eczema. After 2 weeks of treatment, 83% of patients using halobetasol showed complete or marked improvement compared to 28% using vehicle. The medication was well-tolerated with no skin thinning reported.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 224

Results:

Halobetasol was significantly more effective than vehicle in treating chronic eczema

---

---

Halobetasol is generally safe and well-tolerated. Side effects are uncommon (occurring in only 2-5% of patients) and usually mild, mainly including skin dryness, itching, or burning sensations at the application site.

Summary:

Halobetasol propionate cream was as effective as two other steroid creams (clobetasol and betamethasone) in treating severe atopic dermatitis. About 88-93% of patients showed significant improvement, with effects starting within 3 days for about 40% of patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 264

Severity: severe

Age: Not specified

Results:

All three treatments showed similar high success rates

---

Summary:

Halobetasol propionate cream 0.05% was significantly more effective than placebo in treating atopic dermatitis symptoms when applied twice daily for 14 days. The cream improved itching, redness, scaling, and thickened skin, with benefits seen within 7 days of treatment.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 111

Severity: Chronic

Age: Not specified

Results:

Significant improvement in all symptoms compared to vehicle (p<0.001)

---

---

The medication is available in both cream and ointment forms, and can be effective in both adults and children. In pediatric patients, it showed excellent results with 100% success rate for eczema treatment.

Summary:

Halobetasol propionate cream was as effective as two other steroid creams (clobetasol and betamethasone) in treating severe atopic dermatitis. About 88-93% of patients showed significant improvement, with effects starting within 3 days for about 40% of patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 264

Severity: severe

Age: Not specified

Results:

All three treatments showed similar high success rates

---

---

Halobetasol propionate is highly effective at treating eczema, with success rates (defined as 'healed' or 'marked improvement') ranging from 88% to 94% in various studies. It starts working quickly, with many patients seeing improvement within 3 days of starting treatment.

Summary:

Halobetasol propionate cream was found to be as effective as two other steroid creams (clobetasol and betamethasone) in treating severe atopic dermatitis. About 88-90% of patients showed significant improvement, with effects starting within 3 days for about 40% of patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 264

Severity: severe

Age: Not available

Results:

All three treatments showed similar high effectiveness

---

Summary:

Halobetasol propionate ointment was more effective than diflucortolone valerate ointment in treating severe atopic dermatitis, with 91.5% of patients showing significant improvement compared to 83.6%. It also worked faster, with 70% of patients seeing improvements within 3 days, and had fewer side effects.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 120

Results:

Halobetasol propionate showed better overall success rate

---

---

The medication is generally well-tolerated with a low rate of side effects (2-5% of patients). The most common side effects are skin dryness, itching, or burning at the application site.

Summary:

Halobetasol propionate cream was found to be as effective as two other steroid creams (clobetasol and betamethasone) in treating severe atopic dermatitis. About 88-90% of patients showed significant improvement, with effects starting within 3 days for about 40% of patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 264

Severity: severe

Age: Not available

Results:

All three treatments showed similar high effectiveness

---

Summary:

Halobetasol propionate cream 0.05% was significantly more effective than placebo in treating atopic dermatitis symptoms when applied twice daily for 14 days. The medication improved itching, redness, scaling, and thickened skin, with benefits seen within 7 days of treatment.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 111

Results:

Significant improvement in all symptoms compared to vehicle by day 7 and day 14 (p<0.001)

---

---

In children with severe eczema, the combination of halobetasol propionate cream during the day and ointment at night was extremely effective, with a 100% success rate. However, careful monitoring is needed as one case of mild skin thinning was reported.

---

The medication performs as well as or better than other strong topical steroids like clobetasol propionate and betamethasone dipropionate, making it a reliable option for treating severe eczema.

Summary:

Halobetasol propionate cream was found to be as effective as two other steroid creams (clobetasol and betamethasone) in treating severe atopic dermatitis. About 88-90% of patients showed significant improvement, with effects starting within 3 days for about 40% of patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 264

Severity: severe

Age: Not available

Results:

All three treatments showed similar high effectiveness

---

Summary:

Halobetasol propionate ointment was more effective than diflucortolone valerate ointment in treating severe atopic dermatitis, with 91.5% of patients showing significant improvement compared to 83.6%. It also worked faster, with 70% of patients seeing improvements within 3 days, and had fewer side effects.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 120

Results:

Halobetasol propionate showed better overall success rate

---

---

Upadacitinib is highly effective at reducing itch and improving skin symptoms in moderate-to-severe atopic dermatitis, with benefits seen as early as 1-2 weeks of treatment and maintained through 52 weeks

Summary:

Upadacitinib (15mg or 30mg daily) showed rapid improvements in itch, pain, and other eczema symptoms within the first week of treatment. These improvements were maintained for 52 weeks, with patients also experiencing better sleep, quality of life, and mental health.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 1,609

Severity: moderate to severe

Age: 12+

Results:

Upadacitinib showed better results than placebo across all measured outcomes

---

Summary:

Upadacitinib, taken as a daily pill, significantly improved eczema symptoms compared to placebo. After 16 weeks, 60-70% of patients taking upadacitinib 15mg and 73-80% of patients taking 30mg had their eczema improve by at least 75%, compared to only 13-16% of patients taking placebo.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 1,683

Results:

---

---

Upadacitinib shows superior efficacy compared to dupilumab (another common treatment) in improving skin clearance and reducing itch, with faster onset of action

Summary:

This study compared two medications for moderate-to-severe atopic dermatitis: oral upadacitinib and injectable dupilumab. Upadacitinib worked better and faster than dupilumab, with 72.4% of patients seeing major skin improvement after 16 weeks compared to 62.6% with dupilumab. However, upadacitinib had more side effects including acne and infections.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 673

Results:

---

Summary:

Upadacitinib was effective in treating moderate-to-severe eczema in adults, including patients who didn't respond well to other treatments like dupilumab or baricitinib. About 73% of patients achieved significant improvement in their eczema, and 69% experienced reduced itching after 16 weeks of treatment.

Study Type:

Multicenter Study

Studied Population:

Total Patients: 47

Severity: moderate to severe

Age: 18+

Results:

---

---

The most common side effect is acne (occurring in 10-16% of patients), which is usually mild/moderate and manageable. Other potential side effects include increased risk of infections and elevated liver enzymes

Summary:

This study looked at the safety of upadacitinib across multiple conditions including atopic dermatitis by analyzing data from clinical trials. For atopic dermatitis patients, upadacitinib was generally well-tolerated, with acne being a notable side effect specific to AD patients.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 2,693

Severity: not available

Age: not available

Results:

---

---

Upadacitinib significantly improves quality of life measures including sleep, daily activities, and emotional wellbeing in patients with atopic dermatitis

Summary:

Upadacitinib (15mg or 30mg daily) showed rapid improvements in itch, pain, and other eczema symptoms within the first week of treatment. These improvements were maintained for 52 weeks, with patients also experiencing better sleep, quality of life, and mental health.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 1,609

Severity: moderate to severe

Age: 12+

Results:

Upadacitinib showed better results than placebo across all measured outcomes

---

Summary:

Upadacitinib combined with topical steroids significantly improved itch, skin pain, sleep, and quality of life in patients with atopic dermatitis. The improvements were seen within 1-2 weeks and lasted for up to 52 weeks, with 62-84% of patients experiencing meaningful improvements depending on the dose.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 901

Severity: moderate to severe

Age: adolescents and adults

Results:

Both doses showed sustained improvements across all patient-reported outcomes, with higher dose showing better results

---

---

Phototherapy is effective at reducing eczema symptoms and severity in both children and adults with moderate-to-severe eczema. Studies show significant improvements in itching, sleep quality, and overall disease severity scores.

Summary:

Narrow-band UVB light therapy was found to be effective and safe for treating moderate to severe atopic dermatitis in children aged 4-14 years. The treatment improved symptoms significantly, and these improvements lasted for up to 2 years after treatment ended.

Study Type:

Studied Population:

Total Patients: 30

Severity: moderate to severe

Age: 4-14 years

Results:

Treatment improved AD symptoms significantly and maintained improvement for 2 years

---

Summary:

Narrowband UVB light therapy improved symptoms and quality of life for atopic dermatitis patients, with benefits lasting up to 3 months after treatment. The treatment caused only mild side effects like slight redness and burning.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 144

Severity: not available

Age: not available

Results:

PO-SCORAD scores showed significant improvement that lasted for at least 3 months

---

Summary:

Narrowband UVB light therapy helped reduce the need for steroid creams in 70% of eczema patients. About half of the patients achieved clear or almost clear skin after treatment. The therapy also reduced the need for oral steroids and antihistamines.

Study Type:

Multicenter Study

Studied Population:

Total Patients: 844

Severity: not available

Age: not available

Results:

70% of patients needed less topical steroids after treatment

---

---

Phototherapy helps reduce the need for topical steroid creams. One large study found that 70% of patients needed significantly less topical steroids in the 12 months after phototherapy treatment.

Summary:

Narrowband UVB light therapy helped reduce the need for steroid creams in 70% of eczema patients. About half of the patients achieved clear or almost clear skin after treatment. The therapy also reduced the need for oral steroids and antihistamines.

Study Type:

Multicenter Study

Studied Population:

Total Patients: 844

Severity: not available

Age: not available

Results:

70% of patients needed less topical steroids after treatment

---

---

Phototherapy is generally safe with minimal side effects. The most common side effect is dry skin. However, some patients may experience mild redness or burning. People with certain conditions like skin cancer history should not receive phototherapy.

Summary:

Both types of light therapy (narrowband UVB alone or combined with UVA) were equally effective in treating chronic atopic dermatitis. The main difference was that patients receiving only narrowband UVB experienced more skin dryness.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 19

Severity: moderate to severe

Age: not available

Results:

Both types of light therapy were effective in improving eczema severity

---

Summary:

Narrow-band UVB light therapy was found to be effective and safe for treating moderate to severe atopic dermatitis in children aged 4-14 years. The treatment improved symptoms significantly, and these improvements lasted for up to 2 years after treatment ended.

Study Type:

Studied Population:

Total Patients: 30

Severity: moderate to severe

Age: 4-14 years

Results:

Treatment improved AD symptoms significantly and maintained improvement for 2 years

---

---

Different types of phototherapy (NB-UVB and UVA-1) appear to have similar effectiveness, though some studies suggest higher doses may work better for people with darker skin types.

Summary:

Both types of light therapy (narrowband UVB alone or combined with UVA) were equally effective in treating chronic atopic dermatitis. The main difference was that patients receiving only narrowband UVB experienced more skin dryness.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 19

Severity: moderate to severe

Age: not available

Results:

Both types of light therapy were effective in improving eczema severity

---

Summary:

UVA1 phototherapy is effective for treating severe atopic dermatitis. High-dose UVA1 treatment works better than medium-dose for patients with darker skin, while both doses work equally well for patients with fair skin.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 27

Severity: severe

Age: 18+

Results:

Both doses improved SCORAD scores, with high dose being significantly more effective in darker skin types (p<0.0001)

---

---

Cyclosporine works quickly (within 2-3 weeks) and is effective for treating severe atopic dermatitis in both adults and children, but is not recommended for use over one year

Summary:

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Study Type:

Review

Studied Population:

Severity: moderate to severe

Age: not available

Results:

High dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events.

---

Summary:

Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.

Study Type:

Observational Study

Studied Population:

Total Patients: 63

Severity: severe

Age: children (mean 8.4 years)

Results:

---

---

Common side effects include kidney problems (nephrotoxicity), high blood pressure, increased risk of infections, gastrointestinal upset, and abnormal lab results. Children generally tolerate the medication better than adults.

Summary:

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Study Type:

Review

Studied Population:

Severity: moderate to severe

Age: not available

Results:

High dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events.

---

Summary:

Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.

Study Type:

Observational Study

Studied Population:

Total Patients: 63

Severity: severe

Age: children (mean 8.4 years)

Results:

---

---

Studies show cyclosporine and dupilumab (a newer medication) are both effective treatments, with cyclosporine showing faster initial response but dupilumab potentially providing better long-term control

Summary:

Both cyclosporine and methotrexate were effective in treating severe eczema in children and young people. Cyclosporine worked faster, but methotrexate's effects lasted longer after stopping treatment.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 103

Severity: severe

Age: 2-16 years

Results:

---

Summary:

This study compared two medications for moderate-to-severe eczema: dupilumab and cyclosporine. Dupilumab showed better results than cyclosporine in reducing eczema severity, both in the short term (12-16 weeks) and longer term (24-30 weeks). About 75-80% of patients on dupilumab had significant improvement compared to 40-56% on cyclosporine.

Study Type:

Comparative Study

Studied Population:

Total Patients: 163

Severity: moderate to severe

Age: 18+

Results:

Dupilumab showed consistently better results than cyclosporine in achieving 50% improvement in eczema severity

---

---

Drug survival (how long patients stay on the medication) is about 1 year for cyclosporine, with most discontinuations due to either side effects or loss of effectiveness

Summary:

This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.

Study Type:

Comparative Study

Studied Population:

Total Patients: 94

Severity: moderate to severe

Age: 18+

Results:

---

Summary:

Patients with moderate to severe atopic dermatitis stayed on cyclosporine treatment for about 1 year on average. This duration was longer than in patients with psoriasis, who stayed on the medication for about 4.4 months.

Study Type:

Multicenter Study

Studied Population:

Total Patients: 130

Severity: moderate to severe

Age: not available

Results:

Patients with atopic dermatitis stayed on cyclosporine treatment longer than patients with psoriasis

---

---

Topical Vitamin B12 cream appears to be more effective than standard moisturizing creams for treating mild eczema, with studies showing a 78% improvement in symptoms compared to 33.5% with regular creams

Summary:

A vitamin B12 cream was compared to a standard moisturizing cream for treating mild eczema. The vitamin B12 cream reduced eczema severity by 77.6% compared to 33.5% with the standard cream after 12 weeks of use.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 22

Severity: mild

Age: not available

Results:

Vitamin B12 cream was more than twice as effective as standard moisturizer in reducing eczema severity

---

---

There may be a connection between Vitamin B12 blood levels and eczema severity - lower Vitamin B12 levels might be associated with worse eczema symptoms. Oral Vitamin B12 supplements might help improve severe eczema that's difficult to control

Summary:

In a case study of one patient with severe eczema, researchers found that low vitamin B12 levels were associated with worse eczema symptoms. When the patient took vitamin B12 supplements, their eczema improved significantly.

Study Type:

Case Reports

Studied Population:

Total Patients: 1

Severity: severe

Age: 18

Results:

Patient showed meaningful improvement in eczema severity score when taking vitamin B12 supplements

---

---

Vitamin B12 has anti-inflammatory properties and can help regulate the immune system, which may explain why it helps with eczema symptoms

Summary:

In a case study of one patient with severe eczema, researchers found that low vitamin B12 levels were associated with worse eczema symptoms. When the patient took vitamin B12 supplements, their eczema improved significantly.

Study Type:

Case Reports

Studied Population:

Total Patients: 1

Severity: severe

Age: 18

Results:

Patient showed meaningful improvement in eczema severity score when taking vitamin B12 supplements

---

---

Cetirizine is effective at reducing itching and other skin symptoms in both children and adults with atopic dermatitis

Summary:

Cetirizine helped reduce itching and other symptoms of atopic dermatitis in adults, with better results at higher doses (40mg). The medication was most effective at reducing itching, redness, and skin thickening compared to placebo.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 178

Severity: not available

Age: 18+

Results:

Higher doses of cetirizine were more effective at improving symptoms, with 40mg showing the best results

---

---

Long-term use of cetirizine is safe, even in young children. Studies showed no negative effects on behavior, thinking ability, or physical development when used for up to 18 months

Summary:

Cetirizine was found to be safe for long-term use in young children with atopic dermatitis. The medication showed similar or fewer side effects compared to placebo over 18 months of treatment.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 817

Severity: not available

Age: 12-24 months

Results:

This was primarily a safety study

---

---

Cetirizine can help reduce the need for strong topical steroids in patients with moderate-to-severe atopic dermatitis

Summary:

Long-term use of cetirizine in infants with atopic dermatitis helped reduce the need for stronger topical steroids, especially in patients with more severe disease. The medication also significantly reduced the occurrence of hives compared to placebo (5.8% vs 16.2%).

Study Type:

Clinical Trial

Studied Population:

Total Patients: 817

Severity: not specified

Age: 12-24 months

Results:

---

---

In children with atopic dermatitis who are allergic to grass pollen or dust mites, cetirizine may help prevent or delay the development of asthma

Summary:

In infants with atopic dermatitis who were allergic to grass pollen or house dust mites, cetirizine treatment for 18 months helped prevent or delay the development of asthma. This protective effect was particularly strong and lasted for 36 months in children allergic to grass pollen.

Study Type:

Clinical Trial

Studied Population:

Severity: not available

Age: 1-2 years

Results:

Cetirizine prevented/delayed asthma development in sensitized infants

---

---

Dupilumab significantly improves signs and symptoms of moderate-to-severe atopic dermatitis, including skin lesions, itching, and quality of life compared to placebo. In clinical trials, 60-70% of patients achieved a 75% improvement in disease severity scores after 16 weeks of treatment.

Summary:

Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis in adults and children as young as 6 months. Clinical trials show that 60-70% of patients achieve significant improvement in their eczema symptoms, including reduction in itch and skin clearance.

Study Type:

Comment

Studied Population:

Severity: moderate to severe

Age: 6 months and older

Results:

Dupilumab significantly improved eczema symptoms compared to placebo

---

Summary:

Dupilumab significantly improved quality of life in adults with moderate-to-severe eczema. The improvements were meaningful in daily life, particularly reducing pain/discomfort, anxiety/depression, and helping with usual activities.

Study Type:

Studied Population:

Total Patients: 1,379

Severity: moderate to severe

Age: 18+

Results:

Both weekly and every 2 weeks dupilumab treatment led to significantly greater improvements in quality of life compared to placebo

---

Summary:

Dupilumab combined with topical steroids was significantly more effective than steroids alone in treating moderate-to-severe eczema. After 16 weeks, about 39% of patients on dupilumab had clear or almost clear skin compared to 12% on placebo, and these improvements lasted for the full year of treatment.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 740

Severity: moderate to severe

Age: 18+

Results:

---

---

The medication has an acceptable safety profile, with the most common side effects being injection site reactions and conjunctivitis (eye inflammation). Serious side effects are rare. Dupilumab actually reduces skin infections compared to placebo.

Summary:

This real-world study compared the safety of dupilumab to conventional systemic treatments for atopic dermatitis over 5 years. Dupilumab showed fewer side effects related to circulatory, respiratory, and musculoskeletal systems, and infections compared to other treatments. However, it did have a higher risk of eye inflammation (conjunctivitis) compared to some other medications.

Study Type:

Comparative Study

Studied Population:

Results:

---

Summary:

This study compared two medications for moderate-to-severe atopic dermatitis: oral upadacitinib and injectable dupilumab. Upadacitinib worked better and faster than dupilumab, with 72.4% of patients seeing major skin improvement after 16 weeks compared to 62.6% with dupilumab. However, upadacitinib had more side effects including acne and infections.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 673

Results:

---

---

Dupilumab works by blocking two key inflammatory proteins (IL-4 and IL-13) that drive atopic dermatitis. It is administered by subcutaneous injection every 2 weeks, with a higher initial loading dose.

Summary:

Dupilumab is the first approved targeted biological therapy for atopic dermatitis in adults and children over 6 years with moderate-to-severe disease. It works by blocking specific inflammatory proteins (IL-4 and IL-13) and helps improve skin barrier function.

Study Type:

Studied Population:

Severity: moderate to severe

Age: 6 years and older

Results:

---

Summary:

Dupilumab significantly improved eczema symptoms and skin healing over 16 weeks of treatment. The medication worked by reducing inflammation in the skin and helping restore normal skin barrier function.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 54

Severity: moderate-to-severe

Age: not available

Results:

Dupilumab improved skin healing at both molecular and cellular levels

---

---

The medication is approved for patients 6 months and older with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription treatments. Continuous treatment is needed to maintain response.

Summary:

In children aged 6 months to 6 years with moderate-to-severe eczema, dupilumab with low-strength steroid cream worked significantly better than placebo. After 16 weeks, 28% of children on dupilumab had clear or almost clear skin compared to only 4% on placebo, and 53% had major improvement in their eczema compared to 11% on placebo.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 162

Severity: moderate to severe

Age: 6 months to <6 years

Results:

---

Summary:

This study showed that taking dupilumab every 2 weeks maintains improvements in eczema symptoms over 36 weeks. About 72% of patients maintained their improvement when taking dupilumab every 2 weeks, compared to only 30% of patients who stopped treatment. The study found that taking dupilumab less frequently (every 4 or 8 weeks) was not as effective as taking it every 2 weeks.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 422

Results:

---

---

Desonide is effective at treating atopic dermatitis, with studies showing significant improvements in symptoms like itching and inflammation. When combined with moisturizers, it shows even better results with up to 100% effectiveness compared to 60% with desonide alone.

---

Desonide is particularly safe for children, including infants. Studies show it rarely affects the body's natural hormone (cortisol) production, making it safer than stronger steroids like betamethasone.

Summary:

Desonide hydrogel 0.05%, a low-potency steroid, was found to be safe and effective in treating children aged 6 months to 6 years with moderate-to-severe atopic dermatitis. The treatment showed good results in improving symptoms while having minimal impact on the body's hormone system.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 40

Severity: moderate to severe

Age: 6 months-6 years

Results:

Treatment was generally safe with minimal impact on the body's hormone system

---

Summary:

Both desonide 0.05% ointment and hydrocortisone 2.5% ointment were found to be safe for children with atopic dermatitis when used for 4 weeks. Neither medication affected the body's natural cortisol production system.

Study Type:

Clinical Trial

Studied Population:

Results:

Both medications were safe for use in children and did not affect their natural cortisol production system

---

Summary:

Both desonide cream 0.1% and betamethasone cream were equally effective in treating childhood atopic dermatitis. However, desonide had less impact on the body's cortisol levels, making it potentially safer for children.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 29

Severity: Not specified

Age: mean 13.8 months

Results:

Both treatments showed similar clinical effectiveness

---

---

The hydrogel form of desonide helps improve skin moisture and barrier function, with significant improvements seen in as little as 1-2 weeks of treatment.

Summary:

Desonide hydrogel 0.05% was found to be safe and effective in treating mild to moderate atopic dermatitis in children aged 3 months to 18 years. The treatment was well-tolerated and showed significant improvements compared to the vehicle (gel without medication).

Study Type:

Clinical Trial

Studied Population:

Total Patients: 582

Results:

The medication showed significant improvement compared to the vehicle alone

---

---

When used with moisturizers, desonide can help prevent disease recurrence. Studies show this combination can extend the time before symptoms return to about 69 days compared to 49 days with desonide alone.

---

Rocatinlimab significantly improves eczema symptoms compared to placebo. In clinical trials, patients receiving rocatinlimab saw 48-61% reduction in their eczema severity scores after 16 weeks, while those on placebo only saw 15% improvement.

Summary:

Rocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The improvement was seen across all dosing groups, with reductions in disease severity ranging from 48% to 61%, compared to only 15% improvement with placebo.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 274

Results:

---

Summary:

Rocatinlimab is a new medication that blocks a specific receptor (OX40) on immune cells that contribute to eczema. The study showed that it significantly improved eczema symptoms in patients with moderate-to-severe disease. The medication was generally well-tolerated, with fever, common cold symptoms, and chills being the most common side effects.

Study Type:

Clinical Trial

Studied Population:

Severity: moderate to severe

Age: not available

Results:

---

---

The medication shows particularly good results in treating eczema on the head and neck area, which is typically difficult to treat. The improvements in these areas lasted even after stopping treatment, with 77-100% of patients maintaining their improvement 20 weeks after discontinuing the medication.

Summary:

Rocatinlimab showed significant improvement in eczema symptoms across different body areas, particularly in the hard-to-treat head and neck region. The improvements lasted even after stopping treatment, with less than 25% of patients experiencing a return of symptoms in the head and neck area 20 weeks after discontinuation.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 219

Severity: moderate to severe

Age: 18+

Results:

---

---

The most common side effects are fever (17% of patients), common cold symptoms (14%), chills (11%), headache (9%), mouth ulcers (7%), and nausea (6%). These side effects were generally mild and manageable.

Summary:

Rocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The improvement was seen across all dosing groups, with reductions in disease severity ranging from 48% to 61%, compared to only 15% improvement with placebo.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 274

Results:

---

Summary:

Rocatinlimab is a new medication that blocks a specific receptor (OX40) on immune cells that contribute to eczema. The study showed that it significantly improved eczema symptoms in patients with moderate-to-severe disease. The medication was generally well-tolerated, with fever, common cold symptoms, and chills being the most common side effects.

Study Type:

Clinical Trial

Studied Population:

Severity: moderate to severe

Age: not available

Results:

---

---

Unlike some other eczema treatments, rocatinlimab works by targeting a specific immune system receptor called OX40, which helps control inflammatory T-cells. This unique mechanism may explain why improvements continue even after stopping treatment.

Summary:

Two new medications (rocatinlimab and amlitelimab) that work by blocking OX40-OX40L showed promising results in treating moderate-to-severe atopic dermatitis. Both medications showed significant improvement in eczema symptoms, with benefits lasting several weeks after stopping treatment.

Study Type:

Review

Studied Population:

Severity: moderate to severe

Age: not available

Results:

Both medications showed significant improvement in eczema severity compared to placebo, with effects lasting after treatment discontinuation

---

Summary:

Rocatinlimab and amlitelimab are two new medications that work by targeting specific parts of the immune system (OX40-OX40L pathway) in atopic dermatitis. Both medications showed good results in clearing skin and reducing symptoms in patients with moderate-to-severe eczema, with acceptable safety.

Study Type:

Review

Studied Population:

Severity: moderate to severe

Age: not available

Results:

Both medications showed better results than placebo in improving skin clearance and reducing symptoms

---

---

Mycophenolate mofetil has shown good efficacy for treating atopic dermatitis, with studies showing that about 78% of patients achieve partial or full remission of symptoms. It works by suppressing the immune system and typically takes 6-8 weeks to show effects.

Summary:

This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.

Study Type:

Multicenter Study

Studied Population:

Total Patients: 334

Severity: severe

Age: 18+

Results:

---

---

The medication is generally considered safe but requires monitoring. Common side effects include headaches, herpes infections, stomach upset, liver function abnormalities, and reduced blood cell counts. There is also a small risk of developing infections or cancer due to the immune suppression.

Summary:

This real-world study looked at side effects of various medications used to treat atopic dermatitis, including dupilumab and other immunomodulating drugs. The study found some side effects occurred more frequently than expected, particularly eye-related issues and facial redness with dupilumab, and fatigue with methotrexate.

Study Type:

Observational Study

Studied Population:

Total Patients: 266

Severity: not available

Age: adults and pediatric patients

Results:

---

Summary:

This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.

Study Type:

Multicenter Study

Studied Population:

Total Patients: 334

Severity: severe

Age: 18+

Results:

---

---

In rare cases, serious complications can occur. One reported case showed development of Candida infection in the esophagus after 22 months of treatment. Another case reported development of lung disease, though this resolved after stopping the medication.

Summary:

A patient treated with mycophenolate mofetil (MMF) for atopic dermatitis developed a fungal infection in their esophagus after 22 months of treatment. This is a rare complication that hasn't been reported before with MMF treatment.

Study Type:

Case Reports

Studied Population:

Total Patients: 1

Severity: not available

Age: 59

Results:

---

Summary:

A patient with severe atopic dermatitis was treated with mycophenolate mofetil (MMF) and developed lung problems (interstitial lung disease) as a side effect. After stopping MMF and receiving steroid treatment, the patient's lung condition improved.

Study Type:

Case Reports

Studied Population:

Total Patients: 1

Severity: severe

Age: 37 years

Results:

MMF showed good clinical effect but had to be discontinued due to serious side effects

---

---

When compared to other treatments, mycophenolate mofetil appears to have lower effectiveness than newer medications like dupilumab. However, it may still be a useful option for some patients, particularly when other treatments have failed or aren't suitable.

Summary:

This real-world study compared the safety of dupilumab to conventional systemic treatments for atopic dermatitis over 5 years. Dupilumab showed fewer side effects related to circulatory, respiratory, and musculoskeletal systems, and infections compared to other treatments. However, it did have a higher risk of eye inflammation (conjunctivitis) compared to some other medications.

Study Type:

Comparative Study

Studied Population:

Results:

---

Summary:

This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.

Study Type:

Comparative Study

Studied Population:

Total Patients: 94

Severity: moderate to severe

Age: 18+

Results:

---

---

Coconut oil, when formulated with other ingredients (specifically isosorbide diesters), can significantly improve itching in people with mild-to-moderate eczema, showing about 66% improvement in itch symptoms

Summary:

A cream containing coconut and sunflower seed oil derivatives improved itch by 65.6% compared to 43.8% with the control cream in people with mild-to-moderate eczema. The treatment also reduced the need for steroid creams and decreased harmful bacteria on the skin.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 32

Severity: mild to moderate

Age: 18+

Results:

Significantly better itch relief in treatment group (p=0.013)

---

---

When used in a specialized formulation, coconut oil derivatives can help reduce the need for topical steroids in eczema treatment, particularly in the early weeks of treatment

Summary:

A cream containing coconut and sunflower seed oil derivatives improved itch by 65.6% compared to 43.8% with the control cream in people with mild-to-moderate eczema. The treatment also reduced the need for steroid creams and decreased harmful bacteria on the skin.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 32

Severity: mild to moderate

Age: 18+

Results:

Significantly better itch relief in treatment group (p=0.013)

---

---

Coconut oil-based treatments may help reduce harmful bacteria (Staphylococcus aureus) on the skin of eczema patients

Summary:

A cream containing coconut and sunflower seed oil derivatives improved itch by 65.6% compared to 43.8% with the control cream in people with mild-to-moderate eczema. The treatment also reduced the need for steroid creams and decreased harmful bacteria on the skin.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 32

Severity: mild to moderate

Age: 18+

Results:

Significantly better itch relief in treatment group (p=0.013)

---

---

Coconut oil is one of the most commonly used traditional home remedies for eczema treatment, particularly in Indian households

Summary:

In a study of 150 children in India, coconut oil was the most commonly used home remedy for treating eczema/atopic dermatitis, followed by olive oil and mustard oil. The study looked at various home remedies parents used before visiting a doctor.

Study Type:

Observational Study

Studied Population:

Total Patients: 150

Results:

---

---

Elimination diets can be effective for some patients with atopic dermatitis, with about 60% of patients showing improvement in their skin condition when certain foods are removed from their diet

Summary:

In children with severe eczema and gut symptoms, 61% showed improvement when following an elimination diet. The presence of certain immune cells (IgE-positive cells) in the gut could help predict which children would not respond to an elimination diet.

Study Type:

Comparative Study

Studied Population:

Total Patients: 31

Results:

More than half of the children showed improvement with elimination diet

---

---

When food-sensitive patients with atopic dermatitis follow an elimination diet, their allergic responses (measured by IgE antibodies) to problematic foods like eggs or milk decrease over time

Summary:

Elimination diets helped improve symptoms in patients with atopic dermatitis who were sensitive to egg or milk. During the elimination diet, both antibodies to these foods and immune cell responses decreased, suggesting the diet was effective.

Study Type:

Clinical Trial

Studied Population:

Severity: not available

Age: not available

Results:

Elimination diet led to improvement in atopic dermatitis symptoms

---

---

While elimination diets may help some patients, it's difficult to predict who will respond well to the diet just based on standard allergy tests (like skin prick tests or blood tests)

Summary:

In children with severe eczema and gut symptoms, 61% showed improvement when following an elimination diet. The presence of certain immune cells (IgE-positive cells) in the gut could help predict which children would not respond to an elimination diet.

Study Type:

Comparative Study

Studied Population:

Total Patients: 31

Results:

More than half of the children showed improvement with elimination diet

---

Summary:

There is limited scientific evidence that elimination diets help with atopic dermatitis, except in cases where specific food allergies have been confirmed. Food elimination should only be done under medical supervision to avoid nutritional deficiencies.

Study Type:

Comparative Study

Studied Population:

Results:

---

---

Patients who show improvement with elimination diets often experience a reduction in both skin symptoms and internal immune responses

Summary:

Elimination diets helped improve symptoms in patients with atopic dermatitis who were sensitive to egg or milk. During the elimination diet, both antibodies to these foods and immune cell responses decreased, suggesting the diet was effective.

Study Type:

Clinical Trial

Studied Population:

Severity: not available

Age: not available

Results:

Elimination diet led to improvement in atopic dermatitis symptoms

---

Summary:

There is limited scientific evidence that elimination diets help with atopic dermatitis, except in cases where specific food allergies have been confirmed. Food elimination should only be done under medical supervision to avoid nutritional deficiencies.

Study Type:

Comparative Study

Studied Population:

Results:

---

---

When combined with topical corticosteroids, fexofenadine significantly reduces itching (pruritus) in people with atopic dermatitis. The improvement in itching can be noticed after just 1 day of treatment.

Summary:

Adding fexofenadine (an antihistamine) to topical hydrocortisone helped reduce itching in patients with atopic dermatitis more effectively than hydrocortisone alone. The improvement in itching was seen after just 1 day of treatment and continued throughout the study week.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 400

Severity: not available

Age: 16+

Results:

Fexofenadine significantly reduced itching compared to placebo, with improvements seen after 1 day and maintained throughout the week

---

---

Fexofenadine helps reduce itching both during the day and at night, and can decrease the area of skin affected by itching.

Summary:

Adding fexofenadine (an antihistamine) to topical hydrocortisone helped reduce itching in patients with atopic dermatitis more effectively than hydrocortisone alone. The improvement in itching was seen after just 1 day of treatment and continued throughout the study week.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 400

Severity: not available

Age: 16+

Results:

Fexofenadine significantly reduced itching compared to placebo, with improvements seen after 1 day and maintained throughout the week

---

---

Fexofenadine is generally safe to use, with side effects similar to those experienced by people taking a placebo (sugar pill).

Summary:

Adding fexofenadine (an antihistamine) to topical hydrocortisone helped reduce itching in patients with atopic dermatitis more effectively than hydrocortisone alone. The improvement in itching was seen after just 1 day of treatment and continued throughout the study week.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 400

Severity: not available

Age: 16+

Results:

Fexofenadine significantly reduced itching compared to placebo, with improvements seen after 1 day and maintained throughout the week

---

---

Clobetasol propionate is a highly effective treatment for eczema, with studies showing significant improvement in symptoms like redness, itching, and inflammation within 2-4 weeks of treatment

Summary:

Clobetasol propionate cream 0.05% was tested against a vehicle (cream without active ingredient) in patients with moderate-to-severe atopic dermatitis. The study lasted 4 weeks with twice daily application.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 81

Results:

---

Summary:

Clobetasol cream was more effective than fluocinonide cream in treating eczema when applied three times daily for 2 weeks. Clobetasol showed faster healing and fewer side effects (4%) compared to fluocinonide (12%).

Study Type:

Clinical Trial

Studied Population:

Total Patients: 113

Severity: not available

Age: adolescent and adult

Results:

Clobetasol showed faster healing and maintained efficacy, while fluocinonide's healing rate slowed after first week

---

---

The medication can be safely used with minimal side effects when used as directed. Side effects, when they occur, are generally mild and affect about 4% of patients

Summary:

Clobetasol cream was more effective than fluocinonide cream in treating eczema when applied three times daily for 2 weeks. Clobetasol showed faster healing and fewer side effects (4%) compared to fluocinonide (12%).

Study Type:

Clinical Trial

Studied Population:

Total Patients: 113

Severity: not available

Age: adolescent and adult

Results:

Clobetasol showed faster healing and maintained efficacy, while fluocinonide's healing rate slowed after first week

---

Summary:

Clobetasol propionate, a very strong topical steroid, was more effective than flupredniden acetate (medium strength steroid) in preventing hand eczema from coming back. When using clobetasol twice weekly, 70% of patients remained free from eczema flares compared to 30% with flupredniden.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 55

Results:

Clobetasol was more effective at preventing relapses than flupredniden

---

---

Using clobetasol propionate twice weekly as maintenance therapy can help prevent relapses in chronic eczema, with studies showing it kept 70% of patients free from relapses during the observation period

Summary:

Clobetasol propionate, a very strong topical steroid, was more effective than flupredniden acetate (medium strength steroid) in preventing hand eczema from coming back. When using clobetasol twice weekly, 70% of patients remained free from eczema flares compared to 30% with flupredniden.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 55

Results:

Clobetasol was more effective at preventing relapses than flupredniden

---

---

The medication comes in different forms (cream, lotion, ointment) with similar effectiveness, though the lotion form may provide better long-term results after stopping treatment

---

Clobetasol propionate is highly effective at treating eczema, with success rates of over 90% in multiple studies. It typically starts working within a few days and can clear symptoms within 2-4 weeks of treatment.

Summary:

Clobetasol propionate emollient cream 0.05% was tested against a placebo cream in patients with moderate-to-severe atopic dermatitis. The study lasted 4 weeks with twice daily application.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 81

Severity: moderate to severe

Age: ≥12 years

Results:

not available

---

---

When used twice weekly for maintenance therapy, clobetasol can help prevent eczema from coming back. In one study, 70% of patients remained free from relapses using this approach.

Summary:

Clobetasol propionate (a very strong steroid) was more effective than flupredniden acetate (a medium-strength steroid) in preventing hand eczema from coming back. When using clobetasol twice weekly, 70% of patients remained free from eczema flares compared to 30% with flupredniden.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 55

Results:

Clobetasol was more effective at preventing relapses when used twice weekly

---

---

While generally safe for short-term use, side effects can occur in about 4% of patients. These are usually mild but can include skin thinning and temporary changes in cortisol levels. Regular monitoring by a doctor is recommended for long-term use.

Summary:

Clobetasol cream was more effective than fluocinonide cream in treating eczema when applied three times daily for 2 weeks. Clobetasol showed faster healing and fewer side effects (4%) compared to fluocinonide (12%).

Study Type:

Clinical Trial

Studied Population:

Total Patients: 113

Severity: not available

Age: adolescent and adult

Results:

Clobetasol showed faster healing and maintained efficacy, while fluocinonide's healing rate slowed after first week

---

Summary:

Clobetasol propionate emollient cream 0.05% was tested against a placebo cream in patients with moderate-to-severe atopic dermatitis. The study lasted 4 weeks with twice daily application.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 81

Severity: moderate to severe

Age: ≥12 years

Results:

not available

---

---

Different formulations (cream, lotion, emollient) appear to be similarly effective, though some studies suggest the lotion form may provide better long-term results than the cream version.

---

Mupirocin combined with steroid creams (like hydrocortisone or fluticasone) is effective and safe for treating atopic dermatitis, especially when there might be bacterial infection present. In one study, 74% of patients improved with this combination treatment.

Summary:

Using hydrocortisone cream combined with mupirocin was more effective (74% success) than hydrocortisone alone (65% success) or moisturizer (36% success) in treating mild to moderate atopic dermatitis in infants. The combination treatment was safe and helped address potential bacterial infection.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 83

Results:

Combined treatment with hydrocortisone and mupirocin was most effective, followed by hydrocortisone alone, both significantly better than emollient

---

Summary:

A combination ointment containing fluticasone propionate and mupirocin was effective in treating atopic dermatitis with suspected bacterial infection. After 2 weeks of treatment, the majority of patients (67.2%) had only mild disease, and patient comfort improved from 33.65% to 78.60%.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 122

Severity: mild to severe

Age: not available

Results:

Significant improvement in disease severity with majority of patients achieving mild disease status

---

---

Mupirocin cream is as effective as oral antibiotics (like cephalexin) for treating infected eczema, with fewer side effects. It's also preferred by patients because it's applied directly to the skin rather than taken as pills.

Summary:

Mupirocin cream was found to be as effective as oral cephalexin (an antibiotic) for treating infected eczema. The cream worked better at killing bacteria and was preferred by patients over taking oral medication.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 159

Severity: secondarily infected eczema

Age: not available

Results:

Mupirocin cream was similarly effective to oral cephalexin

---

---

While mupirocin can effectively reduce bacteria (particularly Staphylococcus aureus) on the skin during treatment, bacteria levels may return to normal after stopping treatment. However, this doesn't necessarily mean symptoms will get worse.

Summary:

Mupirocin, a topical antibiotic, significantly reduced Staphylococcus aureus bacteria on the skin of atopic dermatitis patients and improved their symptoms. Although bacteria returned after stopping treatment, patients' symptoms didn't get worse during the study period.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 49

Severity: not available

Age: not available

Results:

Mupirocin significantly reduced bacterial counts

---

---

Short-term use of mupirocin appears to be safe, with minimal side effects. The most common side effects reported were mild and included diarrhea and nausea.

Summary:

Mupirocin cream was found to be as effective as oral cephalexin (an antibiotic) for treating infected eczema. The cream worked better at killing bacteria and was preferred by patients over taking oral medication.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 159

Severity: secondarily infected eczema

Age: not available

Results:

Mupirocin cream was similarly effective to oral cephalexin

---

Summary:

Mupirocin, a topical antibiotic, significantly reduced Staphylococcus aureus bacteria on the skin of atopic dermatitis patients and improved their symptoms. Although bacteria returned after stopping treatment, patients' symptoms didn't get worse during the study period.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 49

Severity: not available

Age: not available

Results:

Mupirocin significantly reduced bacterial counts

---

---

Delgocitinib ointment is effective at reducing eczema symptoms in both adults and children. In clinical trials, it significantly improved skin condition and reduced disease severity scores compared to placebo within 4 weeks of treatment.

Summary:

Delgocitinib 0.5% ointment, a new topical treatment for eczema, reduced disease severity by 44.3% after 4 weeks of treatment, while the placebo group showed almost no improvement (1.7%). The medication remained effective for up to 28 weeks and was well-tolerated with mostly mild side effects.

Study Type:

Clinical Trial

Studied Population:

Severity: moderate to severe

Age: 16+

Results:

Delgocitinib significantly improved eczema severity compared to vehicle

---

Summary:

Delgocitinib ointment was tested in Japanese children with eczema and found to reduce disease severity by about 39% after 4 weeks of treatment, while those using a placebo ointment got worse. The medication remained effective for up to 56 weeks and was generally safe to use.

Study Type:

Randomized Controlled Trial

Studied Population:

Severity: moderate

Age: 2-15 years

Results:

Delgocitinib significantly improved eczema symptoms while patients on vehicle got worse

---

Summary:

Delgocitinib ointment (0.25% and 0.5%) significantly improved eczema symptoms in children aged 2-15 years compared to vehicle (placebo) ointment after 4 weeks of treatment. Both concentrations were safe to use and well-tolerated.

Study Type:

Clinical Trial

Studied Population:

Results:

Both concentrations of delgocitinib significantly reduced eczema severity compared to vehicle

---

---

The medication is generally safe and well-tolerated for long-term use (up to 52 weeks in adults and 56 weeks in children). Most side effects were mild and not related to the medication. Common side effects included common cold symptoms and mild skin reactions.

Summary:

Delgocitinib 0.5% ointment was found to be safe and effective for treating atopic dermatitis in Japanese adults when used for up to one year. The improvement in eczema symptoms was maintained throughout the treatment period, and most side effects were mild.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 506

Severity: not available

Age: 16+

Results:

---

Summary:

Delgocitinib ointment was tested in Japanese children with eczema and found to reduce disease severity by about 39% after 4 weeks of treatment, while those using a placebo ointment got worse. The medication remained effective for up to 56 weeks and was generally safe to use.

Study Type:

Randomized Controlled Trial

Studied Population:

Severity: moderate

Age: 2-15 years

Results:

Delgocitinib significantly improved eczema symptoms while patients on vehicle got worse

---

---

Delgocitinib starts working quickly to reduce itching, with improvements noticed as early as the first day of treatment.

Summary:

A new ointment called JTE-052 was tested in Japanese adults with moderate-to-severe eczema. The ointment significantly improved skin symptoms and reduced itching as early as the first night of treatment. All tested strengths (0.25%, 0.5%, 1%, and 3%) worked better than the vehicle (placebo) ointment, with the 3% strength showing the best results.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 327

Severity: moderate to severe

Age: 18+

Results:

All strengths of JTE-052 significantly reduced eczema severity compared to vehicle, with 3% being most effective

---

---

The medication comes in two strengths (0.25% and 0.5%). For children with mild eczema, the 0.5% strength may work better than the 0.25% strength, while both strengths work similarly for moderate to severe cases.

Summary:

Delgocitinib ointment at 0.5% concentration worked better than 0.25% concentration for children with mild eczema, with 71.4% of patients seeing clear or almost clear skin compared to 46.2%. The medication was safe to use for up to 56 weeks, even when combined with other eczema treatments.

Study Type:

Randomized Controlled Trial

Studied Population:

Severity: mild to severe

Age: pediatric (specific range not provided)

Results:

0.5% concentration was more effective for mild cases, while both concentrations showed similar efficacy in moderate-severe cases

---

---

Probiotics appear to be effective in reducing the severity of atopic dermatitis symptoms, with multiple studies showing significant improvements in SCORAD scores (a measure of eczema severity) compared to placebo

Summary:

A probiotic mixture helped improve eczema symptoms in children and teenagers after 12 weeks of treatment. Patients taking probiotics needed less topical steroids between weeks 6-12 of treatment compared to those taking placebo.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 61

Severity: not available

Age: 4-17 years

Results:

Patients taking probiotics had significantly better SCORAD scores compared to placebo

---

Summary:

The probiotic LGG helped improve eczema symptoms in young children when taken daily for 12 weeks. Children who took the probiotic needed less rescue medication and had better quality of life. The benefits were linked to positive changes in both gut and skin bacteria.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 100

Severity: not available

Age: 6-36 months

Results:

Significant improvement in eczema severity that was maintained after treatment

---

Summary:

An 8-week treatment with probiotics (beneficial bacteria) and prebiotics improved eczema symptoms in children. The severity of eczema decreased significantly, with the percentage of children having moderate-severe disease dropping from 92.4% to 28.1%.

Study Type:

Observational Study

Studied Population:

Total Patients: 320

Results:

Significant improvement in eczema severity

---

---

Probiotics may help reduce the need for topical corticosteroids in treating atopic dermatitis, potentially allowing for less steroid use

Summary:

A probiotic mixture helped improve eczema symptoms in children and teenagers after 12 weeks of treatment. Patients taking probiotics needed less topical steroids between weeks 6-12 of treatment compared to those taking placebo.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 61

Severity: not available

Age: 4-17 years

Results:

Patients taking probiotics had significantly better SCORAD scores compared to placebo

---

Summary:

A mixture of probiotics taken by mouth significantly improved eczema symptoms in children with moderate atopic dermatitis. Children taking probiotics needed less topical steroids to manage their condition, with an 83% improvement in symptoms compared to 24% in the placebo group.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 50

Severity: moderate

Age: 4-17 years

Results:

Probiotics led to a significantly greater improvement in eczema severity compared to placebo

---

---

Probiotics appear to be safe with very few reported side effects. Most studies reported similar adverse event rates between probiotic and placebo groups

Summary:

The probiotic LGG helped improve eczema symptoms in young children when taken daily for 12 weeks. Children who took the probiotic needed less rescue medication and had better quality of life. The benefits were linked to positive changes in both gut and skin bacteria.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 100

Severity: not available

Age: 6-36 months

Results:

Significant improvement in eczema severity that was maintained after treatment

---

Summary:

An 8-week treatment with probiotics (beneficial bacteria) and prebiotics improved eczema symptoms in children. The severity of eczema decreased significantly, with the percentage of children having moderate-severe disease dropping from 92.4% to 28.1%.

Study Type:

Observational Study

Studied Population:

Total Patients: 320

Results:

Significant improvement in eczema severity

---

---

Multi-strain probiotic combinations may be more effective than single strains, and treatment duration of 8-12 weeks appears to be optimal for seeing benefits

Summary:

An 8-week treatment with probiotics (beneficial bacteria) and prebiotics improved eczema symptoms in children. The severity of eczema decreased significantly, with the percentage of children having moderate-severe disease dropping from 92.4% to 28.1%.

Study Type:

Observational Study

Studied Population:

Total Patients: 320

Results:

Significant improvement in eczema severity

---

Summary:

Taking specific probiotics and prebiotics for 12 weeks helped improve mild eczema symptoms, including itching and skin lesions. The study suggests that these supplements might help maintain stable eczema and reduce flare-ups.

Study Type:

Observational Study

Studied Population:

Total Patients: 144

Severity: mild

Age: not specified (mean age 25.1 ± 17.6 years)

Results:

All measures of eczema severity showed significant improvement after 12 weeks of probiotic treatment

---

---

Loratadine can help reduce itching (pruritus) in people with atopic dermatitis, both during the day and night. More than half of patients showed positive response to the treatment.

Summary:

Loratadine significantly reduced itching (pruritus) in patients with atopic dermatitis compared to placebo, both during day and night. At least 9 out of 16 patients responded positively to the treatment.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 16

Results:

Majority of patients (at least 56%) responded positively to loratadine treatment

---

Summary:

Loratadine was found to be as effective as hydroxyzine in treating atopic dermatitis symptoms, reducing symptoms by 57%. Importantly, loratadine caused much less drowsiness than hydroxyzine, with only one patient reporting sleepiness compared to eight patients on hydroxyzine.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 41

Severity: not available

Age: 18-65

Results:

Loratadine showed better symptom reduction than both hydroxyzine and placebo

---

---

Loratadine is as effective as hydroxyzine (another antihistamine) for treating symptoms, but causes much less drowsiness. Only 5% of patients on loratadine reported feeling sleepy compared to 40% of those taking hydroxyzine.

Summary:

Loratadine was found to be as effective as hydroxyzine in treating atopic dermatitis symptoms, reducing symptoms by 57%. Importantly, loratadine caused much less drowsiness than hydroxyzine, with only one patient reporting sleepiness compared to eight patients on hydroxyzine.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 41

Severity: not available

Age: 18-65

Results:

Loratadine showed better symptom reduction than both hydroxyzine and placebo

---

---

When used alongside strong topical steroids (like mometasone cream), loratadine may not provide additional benefits, though it remains safe to use with no serious side effects.

Summary:

The study found that adding loratadine (an antihistamine) to mometasone cream treatment did not provide additional benefits for children with atopic dermatitis. The mometasone cream alone was very effective in treating the condition.

Study Type:

Clinical Trial

Studied Population:

Total Patients: 48

Severity: not available

Age: mean age 73.67 months (approximately 6 years)

Results:

Both groups showed significant improvement, with no difference between loratadine and placebo groups (p = 0.99)

---

---

A newer version of loratadine (desloratadine) combined with other medications may be effective for treating eczema and reducing inflammation.

Summary:

The combination of desloratadine citrate and compound glycyrrhizin was more effective in treating subacute eczema compared to compound glycyrrhizin alone. The combination therapy showed lower inflammation markers and fewer side effects.

Study Type:

Randomized Controlled Trial

Studied Population:

Total Patients: 100

Severity: subacute

Age: not available

Results:

The combination therapy was more effective in reducing inflammation

---

---